InMed Pharmaceuticals Inc. (NASDAQ: INM) Stock Competitors & Peer Comparison

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, TAK has a market cap of 58.7B. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while TAK trades at $18.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas TAK's P/E ratio is 13.27. In terms of profitability, INM's ROE is -0.73%, compared to TAK's ROE of +0.02%. Regarding short-term risk, INM is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for INM.Check TAK's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, TEVA has a market cap of 42.3B. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while TEVA trades at $36.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas TEVA's P/E ratio is 12.41. In terms of profitability, INM's ROE is -0.73%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, INM is less volatile compared to TEVA. This indicates lower risk in terms of short-term price fluctuations for INM.Check TEVA's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, HLN has a market cap of 42.3B. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while HLN trades at $9.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas HLN's P/E ratio is 17.90. In terms of profitability, INM's ROE is -0.73%, compared to HLN's ROE of +0.17%. Regarding short-term risk, INM is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for INM.Check HLN's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, ZTS has a market cap of 31.8B. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while ZTS trades at $74.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas ZTS's P/E ratio is 11.52. In terms of profitability, INM's ROE is -0.73%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, INM is more volatile compared to ZTS. This indicates higher risk in terms of short-term price fluctuations for INM.Check ZTS's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, VTRS has a market cap of 19.7B. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while VTRS trades at $16.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas VTRS's P/E ratio is 6.70. In terms of profitability, INM's ROE is -0.73%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, INM is more volatile compared to VTRS. This indicates higher risk in terms of short-term price fluctuations for INM.Check VTRS's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while ITCI trades at $131.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas ITCI's P/E ratio is -180.64. In terms of profitability, INM's ROE is -0.73%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, INM is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for INM.Check ITCI's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, ELAN has a market cap of 12.2B. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while ELAN trades at $24.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas ELAN's P/E ratio is 23.07. In terms of profitability, INM's ROE is -0.73%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, INM is more volatile compared to ELAN. This indicates higher risk in terms of short-term price fluctuations for INM.Check ELAN's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while CTLT trades at $63.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas CTLT's P/E ratio is -27.84. In terms of profitability, INM's ROE is -0.73%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, INM is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for INM.Check CTLT's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, RDY has a market cap of 10B. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while RDY trades at $11.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas RDY's P/E ratio is 19.62. In terms of profitability, INM's ROE is -0.73%, compared to RDY's ROE of +0.09%. Regarding short-term risk, INM is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for INM.Check RDY's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, ALKS has a market cap of 7.7B. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while ALKS trades at $46.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas ALKS's P/E ratio is 48.53. In terms of profitability, INM's ROE is -0.73%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, INM is less volatile compared to ALKS. This indicates lower risk in terms of short-term price fluctuations for INM.Check ALKS's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while LNTH trades at $100.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas LNTH's P/E ratio is 16.97. In terms of profitability, INM's ROE is -0.73%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, INM is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for INM.Check LNTH's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, AMRX has a market cap of 5.6B. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while AMRX trades at $17.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas AMRX's P/E ratio is 19.38. In terms of profitability, INM's ROE is -0.73%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, INM is less volatile compared to AMRX. This indicates lower risk in terms of short-term price fluctuations for INM.Check AMRX's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, INDV has a market cap of 4.4B. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while INDV trades at $34.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas INDV's P/E ratio is 9.57. In terms of profitability, INM's ROE is -0.73%, compared to INDV's ROE of -2.16%. Regarding short-term risk, INM is more volatile compared to INDV. This indicates higher risk in terms of short-term price fluctuations for INM.Check INDV's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, RGC has a market cap of 3.4B. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while RGC trades at $6.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas RGC's P/E ratio is -485.21. In terms of profitability, INM's ROE is -0.73%, compared to RGC's ROE of -2.32%. Regarding short-term risk, INM is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for INM.Check RGC's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, ALVOW has a market cap of 2.8B. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while ALVOW trades at $0.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas ALVOW's P/E ratio is 43.73. In terms of profitability, INM's ROE is -0.73%, compared to ALVOW's ROE of +0.77%. Regarding short-term risk, INM is more volatile compared to ALVOW. This indicates higher risk in terms of short-term price fluctuations for INM.Check ALVOW's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, SUPN has a market cap of 2.5B. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while SUPN trades at $42.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas SUPN's P/E ratio is 14.23. In terms of profitability, INM's ROE is -0.73%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, INM is more volatile compared to SUPN. This indicates higher risk in terms of short-term price fluctuations for INM.Check SUPN's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, HCM has a market cap of 2.5B. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while HCM trades at $13.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas HCM's P/E ratio is 5.28. In terms of profitability, INM's ROE is -0.73%, compared to HCM's ROE of +0.01%. Regarding short-term risk, INM is less volatile compared to HCM. This indicates lower risk in terms of short-term price fluctuations for INM.Check HCM's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, BHC has a market cap of 2.5B. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while BHC trades at $6.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas BHC's P/E ratio is 1.67. In terms of profitability, INM's ROE is -0.73%, compared to BHC's ROE of +0.89%. Regarding short-term risk, INM is less volatile compared to BHC. This indicates lower risk in terms of short-term price fluctuations for INM.Check BHC's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while DCPH trades at $25.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas DCPH's P/E ratio is -11.58. In terms of profitability, INM's ROE is -0.73%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, INM is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for INM.Check DCPH's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while AVDL trades at $21.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, INM's ROE is -0.73%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, INM is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for INM.Check AVDL's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, PRGO has a market cap of 2.1B. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while PRGO trades at $14.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas PRGO's P/E ratio is 5.97. In terms of profitability, INM's ROE is -0.73%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, INM is less volatile compared to PRGO. This indicates lower risk in terms of short-term price fluctuations for INM.Check PRGO's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, TRLV has a market cap of 2.1B. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while TRLV trades at $12.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas TRLV's P/E ratio is -4.92. In terms of profitability, INM's ROE is -0.73%, compared to TRLV's ROE of -0.44%. Regarding short-term risk, INM is more volatile compared to TRLV. This indicates higher risk in terms of short-term price fluctuations for INM.Check TRLV's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while EMBCV trades at $33.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas EMBCV's P/E ratio is N/A. In terms of profitability, INM's ROE is -0.73%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, INM is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for INM.Check EMBCV's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while DVAX trades at $15.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas DVAX's P/E ratio is -41.89. In terms of profitability, INM's ROE is -0.73%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, INM is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for INM.Check DVAX's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, ALVO has a market cap of 1.8B. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while ALVO trades at $5.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas ALVO's P/E ratio is -15.65. In terms of profitability, INM's ROE is -0.73%, compared to ALVO's ROE of +0.77%. Regarding short-term risk, INM is more volatile compared to ALVO. This indicates higher risk in terms of short-term price fluctuations for INM.Check ALVO's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, ANIP has a market cap of 1.6B. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while ANIP trades at $70.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas ANIP's P/E ratio is 8.67. In terms of profitability, INM's ROE is -0.73%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, INM is less volatile compared to ANIP. This indicates lower risk in terms of short-term price fluctuations for INM.Check ANIP's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while TARO trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas TARO's P/E ratio is 30.05. In terms of profitability, INM's ROE is -0.73%, compared to TARO's ROE of +0.03%. Regarding short-term risk, INM is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for INM.Check TARO's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, ETON has a market cap of 1.6B. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while ETON trades at $58.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas ETON's P/E ratio is 127.07. In terms of profitability, INM's ROE is -0.73%, compared to ETON's ROE of +0.40%. Regarding short-term risk, INM is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for INM.Check ETON's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, PAHC has a market cap of 1.6B. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while PAHC trades at $37.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas PAHC's P/E ratio is 13.05. In terms of profitability, INM's ROE is -0.73%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, INM is less volatile compared to PAHC. This indicates lower risk in terms of short-term price fluctuations for INM.Check PAHC's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, HROW has a market cap of 1.4B. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while HROW trades at $37.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas HROW's P/E ratio is -38.93. In terms of profitability, INM's ROE is -0.73%, compared to HROW's ROE of -1.04%. Regarding short-term risk, INM is less volatile compared to HROW. This indicates lower risk in terms of short-term price fluctuations for INM.Check HROW's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while CRON trades at $3.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas CRON's P/E ratio is 30.96. In terms of profitability, INM's ROE is -0.73%, compared to CRON's ROE of +0.06%. Regarding short-term risk, INM is less volatile compared to CRON. This indicates lower risk in terms of short-term price fluctuations for INM.Check CRON's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, PCRX has a market cap of 1B. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while PCRX trades at $25.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas PCRX's P/E ratio is 10.13. In terms of profitability, INM's ROE is -0.73%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, INM is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for INM.Check PCRX's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, AMPH has a market cap of 1B. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while AMPH trades at $22.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas AMPH's P/E ratio is 7.91. In terms of profitability, INM's ROE is -0.73%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, INM is less volatile compared to AMPH. This indicates lower risk in terms of short-term price fluctuations for INM.Check AMPH's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while PETQ trades at $30.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas PETQ's P/E ratio is 83.73. In terms of profitability, INM's ROE is -0.73%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, INM is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for INM.Check PETQ's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, COLL has a market cap of 763.2M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while COLL trades at $23.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas COLL's P/E ratio is 2.95. In terms of profitability, INM's ROE is -0.73%, compared to COLL's ROE of +0.16%. Regarding short-term risk, INM is less volatile compared to COLL. This indicates lower risk in terms of short-term price fluctuations for INM.Check COLL's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, IRWD has a market cap of 701.3M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while IRWD trades at $4.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas IRWD's P/E ratio is 5.46. In terms of profitability, INM's ROE is -0.73%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, INM is less volatile compared to IRWD. This indicates lower risk in terms of short-term price fluctuations for INM.Check IRWD's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, GLAS has a market cap of 682.1M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while GLAS trades at $8.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas GLAS's P/E ratio is -15.74. In terms of profitability, INM's ROE is -0.73%, compared to GLAS's ROE of -0.51%. Regarding short-term risk, INM is less volatile compared to GLAS. This indicates lower risk in terms of short-term price fluctuations for INM.Check GLAS's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, AQST has a market cap of 670M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while AQST trades at $5.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas AQST's P/E ratio is -8.22. In terms of profitability, INM's ROE is -0.73%, compared to AQST's ROE of +2.44%. Regarding short-term risk, INM is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for INM.Check AQST's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, EVO has a market cap of 660.7M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while EVO trades at $1.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas EVO's P/E ratio is -2.63. In terms of profitability, INM's ROE is -0.73%, compared to EVO's ROE of -0.27%. Regarding short-term risk, INM is more volatile compared to EVO. This indicates higher risk in terms of short-term price fluctuations for INM.Check EVO's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, EOLS has a market cap of 612.4M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while EOLS trades at $8.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas EOLS's P/E ratio is -29.45. In terms of profitability, INM's ROE is -0.73%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, INM is less volatile compared to EOLS. This indicates lower risk in terms of short-term price fluctuations for INM.Check EOLS's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while BDSI trades at $5.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas BDSI's P/E ratio is 6.82. In terms of profitability, INM's ROE is -0.73%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, INM is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for INM.Check BDSI's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, TLRY has a market cap of 503.2M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while TLRY trades at $4.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas TLRY's P/E ratio is -4.15. In terms of profitability, INM's ROE is -0.73%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, INM is less volatile compared to TLRY. This indicates lower risk in terms of short-term price fluctuations for INM.Check TLRY's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, KMDA has a market cap of 492.7M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while KMDA trades at $8.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas KMDA's P/E ratio is 22.47. In terms of profitability, INM's ROE is -0.73%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, INM is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for INM.Check KMDA's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, CGC has a market cap of 410.6M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while CGC trades at $0.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas CGC's P/E ratio is -2.18. In terms of profitability, INM's ROE is -0.73%, compared to CGC's ROE of -0.33%. Regarding short-term risk, INM is more volatile compared to CGC. This indicates higher risk in terms of short-term price fluctuations for INM.Check CGC's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, TKNO has a market cap of 371M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while TKNO trades at $7.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas TKNO's P/E ratio is -22.32. In terms of profitability, INM's ROE is -0.73%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, INM is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for INM.Check TKNO's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, EBS has a market cap of 319.9M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while EBS trades at $6.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas EBS's P/E ratio is 4.31. In terms of profitability, INM's ROE is -0.73%, compared to EBS's ROE of -0.36%. Regarding short-term risk, INM is less volatile compared to EBS. This indicates lower risk in terms of short-term price fluctuations for INM.Check EBS's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while ALIM trades at $5.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas ALIM's P/E ratio is 5.28. In terms of profitability, INM's ROE is -0.73%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, INM is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for INM.Check ALIM's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while LNDC trades at $8.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas LNDC's P/E ratio is -4.04. In terms of profitability, INM's ROE is -0.73%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, INM is less volatile compared to LNDC. This indicates lower risk in terms of short-term price fluctuations for INM.Check LNDC's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, CRDL has a market cap of 253.6M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while CRDL trades at $2.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas CRDL's P/E ratio is -8.77. In terms of profitability, INM's ROE is -0.73%, compared to CRDL's ROE of -1.94%. Regarding short-term risk, INM is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for INM.Check CRDL's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, ACB has a market cap of 244.7M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while ACB trades at $3.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas ACB's P/E ratio is -8.06. In terms of profitability, INM's ROE is -0.73%, compared to ACB's ROE of -0.21%. Regarding short-term risk, INM is less volatile compared to ACB. This indicates lower risk in terms of short-term price fluctuations for INM.Check ACB's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, SIGA has a market cap of 236M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while SIGA trades at $3.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas SIGA's P/E ratio is 12.19. In terms of profitability, INM's ROE is -0.73%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, INM is less volatile compared to SIGA. This indicates lower risk in terms of short-term price fluctuations for INM.Check SIGA's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while TYHT trades at $11.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas TYHT's P/E ratio is -1.61. In terms of profitability, INM's ROE is -0.73%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, INM is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for INM.Check TYHT's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, ORGO has a market cap of 220M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while ORGO trades at $1.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas ORGO's P/E ratio is 57.00. In terms of profitability, INM's ROE is -0.73%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, INM is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for INM.Check ORGO's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, DERM has a market cap of 216.3M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while DERM trades at $7.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas DERM's P/E ratio is -21.24. In terms of profitability, INM's ROE is -0.73%, compared to DERM's ROE of -0.20%. Regarding short-term risk, INM is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for INM.Check DERM's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while REPH trades at $2.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas REPH's P/E ratio is -8.04. In terms of profitability, INM's ROE is -0.73%, compared to REPH's ROE of -0.22%. Regarding short-term risk, INM is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for INM.Check REPH's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, LFCR has a market cap of 165M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while LFCR trades at $4.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas LFCR's P/E ratio is -4.11. In terms of profitability, INM's ROE is -0.73%, compared to LFCR's ROE of -3.77%. Regarding short-term risk, INM is less volatile compared to LFCR. This indicates lower risk in terms of short-term price fluctuations for INM.Check LFCR's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, OGI has a market cap of 162.6M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while OGI trades at $1.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas OGI's P/E ratio is 2.59. In terms of profitability, INM's ROE is -0.73%, compared to OGI's ROE of +0.21%. Regarding short-term risk, INM is less volatile compared to OGI. This indicates lower risk in terms of short-term price fluctuations for INM.Check OGI's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while THTX trades at $3.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas THTX's P/E ratio is -28.83. In terms of profitability, INM's ROE is -0.73%, compared to THTX's ROE of +0.36%. Regarding short-term risk, INM is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for INM.Check THTX's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while ASRT trades at $23.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas ASRT's P/E ratio is -7.10. In terms of profitability, INM's ROE is -0.73%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, INM is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for INM.Check ASRT's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while SCTL trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas SCTL's P/E ratio is -7.86. In terms of profitability, INM's ROE is -0.73%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, INM is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for INM.Check SCTL's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, BGM has a market cap of 108.5M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while BGM trades at $0.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas BGM's P/E ratio is -0.98. In terms of profitability, INM's ROE is -0.73%, compared to BGM's ROE of -0.05%. Regarding short-term risk, INM is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for INM.Check BGM's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while PROC trades at $1.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas PROC's P/E ratio is 1.53. In terms of profitability, INM's ROE is -0.73%, compared to PROC's ROE of -2.22%. Regarding short-term risk, INM is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for INM.Check PROC's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, CPIX has a market cap of 101.7M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while CPIX trades at $6.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas CPIX's P/E ratio is -16.97. In terms of profitability, INM's ROE is -0.73%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, INM is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for INM.Check CPIX's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while OPTN trades at $9.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas OPTN's P/E ratio is -4.42. In terms of profitability, INM's ROE is -0.73%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, INM is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for INM.Check OPTN's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while ZOM trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas ZOM's P/E ratio is -1.62. In terms of profitability, INM's ROE is -0.73%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, INM is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for INM.Check ZOM's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while GRVI trades at $4.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas GRVI's P/E ratio is 26.05. In terms of profitability, INM's ROE is -0.73%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, INM is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for INM.Check GRVI's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, ZYBT has a market cap of 76.3M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while ZYBT trades at $1.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas ZYBT's P/E ratio is -7.32. In terms of profitability, INM's ROE is -0.73%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, INM is more volatile compared to ZYBT. This indicates higher risk in terms of short-term price fluctuations for INM.Check ZYBT's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while ZYNE trades at $1.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, INM's ROE is -0.73%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, INM is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for INM.Check ZYNE's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while SSIC trades at $10.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas SSIC's P/E ratio is 11.93. In terms of profitability, INM's ROE is -0.73%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, INM is less volatile compared to SSIC. This indicates lower risk in terms of short-term price fluctuations for INM.Check SSIC's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, INCR has a market cap of 64.2M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while INCR trades at $5.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas INCR's P/E ratio is -12.51. In terms of profitability, INM's ROE is -0.73%, compared to INCR's ROE of -0.09%. Regarding short-term risk, INM is less volatile compared to INCR. This indicates lower risk in terms of short-term price fluctuations for INM.Check INCR's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, TLPH has a market cap of 62.3M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while TLPH trades at $1.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas TLPH's P/E ratio is -3.87. In terms of profitability, INM's ROE is -0.73%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, INM is less volatile compared to TLPH. This indicates lower risk in terms of short-term price fluctuations for INM.Check TLPH's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while VLNS trades at $0.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas VLNS's P/E ratio is -1.03. In terms of profitability, INM's ROE is -0.73%, compared to VLNS's ROE of N/A. Regarding short-term risk, INM is less volatile compared to VLNS. This indicates lower risk in terms of short-term price fluctuations for INM.Check VLNS's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while DRRX trades at $1.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas DRRX's P/E ratio is -4.44. In terms of profitability, INM's ROE is -0.73%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, INM is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for INM.Check DRRX's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while JUPW trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas JUPW's P/E ratio is -2.41. In terms of profitability, INM's ROE is -0.73%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, INM is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for INM.Check JUPW's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while QLI trades at $5.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas QLI's P/E ratio is -4.92. In terms of profitability, INM's ROE is -0.73%, compared to QLI's ROE of -0.16%. Regarding short-term risk, INM is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for INM.Check QLI's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, CPHI has a market cap of 33.2M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while CPHI trades at $0.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas CPHI's P/E ratio is -1.91. In terms of profitability, INM's ROE is -0.73%, compared to CPHI's ROE of -0.17%. Regarding short-term risk, INM is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for INM.Check CPHI's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, RMTI has a market cap of 31.5M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while RMTI trades at $7.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas RMTI's P/E ratio is -5.96. In terms of profitability, INM's ROE is -0.73%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, INM is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for INM.Check RMTI's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while HEXO trades at $0.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas HEXO's P/E ratio is -0.26. In terms of profitability, INM's ROE is -0.73%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, INM is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for INM.Check HEXO's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, TXMD has a market cap of 25.6M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while TXMD trades at $2.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas TXMD's P/E ratio is 112.58. In terms of profitability, INM's ROE is -0.73%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, INM is less volatile compared to TXMD. This indicates lower risk in terms of short-term price fluctuations for INM.Check TXMD's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, AYTU has a market cap of 23.7M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while AYTU trades at $2.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas AYTU's P/E ratio is -1.15. In terms of profitability, INM's ROE is -0.73%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, INM is less volatile compared to AYTU. This indicates lower risk in terms of short-term price fluctuations for INM.Check AYTU's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while CYTH trades at $0.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas CYTH's P/E ratio is -0.80. In terms of profitability, INM's ROE is -0.73%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, INM is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for INM.Check CYTH's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while EVOK trades at $11.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas EVOK's P/E ratio is -7.97. In terms of profitability, INM's ROE is -0.73%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, INM is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for INM.Check EVOK's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, OPTH has a market cap of 15.4M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while OPTH trades at $4.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas OPTH's P/E ratio is -17.48. In terms of profitability, INM's ROE is -0.73%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, INM is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for INM.Check OPTH's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while ACRX trades at $0.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas ACRX's P/E ratio is -0.31. In terms of profitability, INM's ROE is -0.73%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, INM is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for INM.Check ACRX's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, CABR has a market cap of 11.5M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while CABR trades at $1.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas CABR's P/E ratio is -2.25. In terms of profitability, INM's ROE is -0.73%, compared to CABR's ROE of -3.86%. Regarding short-term risk, INM is less volatile compared to CABR. This indicates lower risk in terms of short-term price fluctuations for INM.Check CABR's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while AGRX trades at $1.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas AGRX's P/E ratio is -0.89. In terms of profitability, INM's ROE is -0.73%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, INM is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for INM.Check AGRX's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, GELS has a market cap of 8.3M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while GELS trades at $0.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas GELS's P/E ratio is -1.80. In terms of profitability, INM's ROE is -0.73%, compared to GELS's ROE of -0.25%. Regarding short-term risk, INM is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for INM.Check GELS's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while NLTX trades at $3.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas NLTX's P/E ratio is -0.28. In terms of profitability, INM's ROE is -0.73%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, INM is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for INM.Check NLTX's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while LCI trades at $0.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas LCI's P/E ratio is -0.04. In terms of profitability, INM's ROE is -0.73%, compared to LCI's ROE of +1.66%. Regarding short-term risk, INM is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for INM.Check LCI's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while ADMP trades at $0.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas ADMP's P/E ratio is -0.08. In terms of profitability, INM's ROE is -0.73%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, INM is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for INM.Check ADMP's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, YCBD has a market cap of 5.1M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while YCBD trades at $0.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas YCBD's P/E ratio is -1.21. In terms of profitability, INM's ROE is -0.73%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, INM is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for INM.Check YCBD's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while MNK trades at $0.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas MNK's P/E ratio is -0.44. In terms of profitability, INM's ROE is -0.73%, compared to MNK's ROE of -0.36%. Regarding short-term risk, INM is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for INM.Check MNK's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while FLGC trades at $7.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas FLGC's P/E ratio is -0.19. In terms of profitability, INM's ROE is -0.73%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, INM is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for INM.Check FLGC's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, SBFM has a market cap of 2.7M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while SBFM trades at $1.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas SBFM's P/E ratio is -0.19. In terms of profitability, INM's ROE is -0.73%, compared to SBFM's ROE of -0.24%. Regarding short-term risk, INM is less volatile compared to SBFM. This indicates lower risk in terms of short-term price fluctuations for INM.Check SBFM's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, UPC has a market cap of 2.5M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while UPC trades at $4.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas UPC's P/E ratio is -0.50. In terms of profitability, INM's ROE is -0.73%, compared to UPC's ROE of -0.03%. Regarding short-term risk, INM is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for INM.Check UPC's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while PLXP trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas PLXP's P/E ratio is -0.22. In terms of profitability, INM's ROE is -0.73%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, INM is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for INM.Check PLXP's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while ATNX trades at $0.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas ATNX's P/E ratio is -0.02. In terms of profitability, INM's ROE is -0.73%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, INM is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for INM.Check ATNX's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, RDHL has a market cap of 2.3M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while RDHL trades at $0.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas RDHL's P/E ratio is 0.14. In terms of profitability, INM's ROE is -0.73%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, INM is less volatile compared to RDHL. This indicates lower risk in terms of short-term price fluctuations for INM.Check RDHL's competition here

InMed Pharmaceuticals Inc. (NASDAQ: INM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INM stands at 2.5M. In comparison, SNOA has a market cap of 2.2M. Regarding current trading prices, INM is priced at $1.37 on the NASDAQ, while SNOA trades at $1.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INM currently has a P/E ratio of -0.25, whereas SNOA's P/E ratio is -1.12. In terms of profitability, INM's ROE is -0.73%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, INM is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for INM.Check SNOA's competition here